CAC
EUCR

Cowen and Company’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Cowen and Company’s Portfolio EUCR Stock Details EUCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-65,296
Closed -$652K – 762
2021
Q1 		$652K Buy
+65,296
New +$670K 0.04% 168

Other funds holding EUCR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.28% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cowen and Company's EUCR Position: Q2 2021 in Review

Cowen and Company sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q2 2021, closing a stake of 65,296 shares — an estimated $652K sold.

Cowen and Company first reported a position in EUCR in Q1 2021 and held it in 1 quarter. The position peaked at $652K in Q1 2021. 31 funds tracked by Wall St. Rank hold EUCR as of Q2 2021.

  • Cowen and Company reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q2 2021 after selling out during the quarter.
  • Cowen and Company sold 65,296 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q2 2021, an estimated $652K.
  • Cowen and Company first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q1 2021 and held it in 1 quarter.
  • Cowen and Company's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $652K in Q1 2021.
  • 31 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q2 2021.

Based on Cowen and Company's 13F filing for Q2 2021, filed 13 Aug 2021.